Valeo Financial Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Valeo Financial Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,177	Closed	-$12.6K	–	721
2023 Q4	$12.6K	Sell	1,177 -550	-32%	-$3.96K	﹤0.01%	631
2023 Q3	$10.4K	Hold	1,727	–	–	﹤0.01%	614
2023 Q2	$11.9K	Hold	1,727	–	–	﹤0.01%	587
2023 Q1	$27.1K	Hold	1,727	–	–	﹤0.01%	598
2022 Q4	$34.5K	Hold	1,727	–	–	﹤0.01%	521
2022 Q3	$31K	Hold	1,727	–	–	﹤0.01%	487
2022 Q2	$38K	Hold	1,727	–	–	﹤0.01%	479
2022 Q1	$48K	Hold	1,727	–	–	﹤0.01%	598
2021 Q4	$78K	Hold	1,727	–	–	﹤0.01%	554
2021 Q3	$144K	Buy	+1,727	New	+$143K	0.01%	522
2021 Q2	–	Sell	-175	Closed	-$29K	–	1962
2021 Q1	$29K	Buy	+175	New	+$23.1K	﹤0.01%	1048

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Valeo Financial Advisors's ONCT Position: Q1 2024 in Review

Valeo Financial Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 1,177 shares — an estimated $12.6K sold.

Valeo Financial Advisors first reported a position in ONCT in Q1 2021 and held it in 11 quarters. The position peaked at $144K in Q3 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Valeo Financial Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Valeo Financial Advisors sold 1,177 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.6K.
Valeo Financial Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Valeo Financial Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $144K in Q3 2021.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Valeo Financial Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.